(19) 대한민국특허청(KR) (12) 공개특허공보(A) - Questel

[1201]
interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma:
effect on lymphoma growth and on B clinical Symptoms, Blood, 1994 Oct 15; 84(8):2472-9; Smith PC, et
al, Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in
nude mice, Prostate, 2001 Jun 15;48(1):47-53; Smith PC, et al, Interleukin-6 and prostate cancer
progression, Cytokine Growth Factor Rev., 2001 Mar;12(1):33-40; Chung TD, et al, Characterization of
the role of IL-6 in the progression of prostate cancer, Prostate, 1999 Feb 15;38(3):199-207; Okamoto
M, et al, Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells
in vitro, Cancer Res., 1997 Jan 1;57(1):141-6; Reittie JE, et al, Interleukin-6 inhibits apoptosis and
tumor necrosis factor induced proliferation of B-chronic lymphocytic leukemia, Leuk Lymphoma, 1996
Jun;22(1-2):83-90, follow 186, color plate VI; Sugiyama H, et al, The expression of IL-6 and its
related genes in acute leukemia, Leuk Lymphoma, 1996 Mar;21(1-2):49-52; Bataille R, et al, Effects of
an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia,
Med Oncol Tumor Pharmacother., 1993;10(4):185-8; Kedar I, et al, Thalidomide reduces serum C-reactive
protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer
patients who failed IL-2-based therapy, Int J Cancer, 2004 Jun 10;110(2):260-5; Angelo LS, Talpaz M,
Kurzrock R, Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement
of p53, Cancer Res., 2002 Feb 1;62(3):932-40; Nishimoto N, Humanized anti-interleukin-6 receptor
antibody treatment of multicentric Castleman disease, Blood, 2005 Oct 15;106(8):2627-32, Epub 2005 Jul
5; Katsume A, et al, Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like
symptoms emerged in IL-6 transgenic mice, Cytokine, 2002 Dec 21;20(6):304-11; Nishimoto N, et al,
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy, Blood,
2000 Jan 1;95(1):56-61; Screpanti I, Inactivation of the IL-6 gene prevents development of
multicentric Castleman's disease in C/EBP betamice, J Exp Med., 1996 Oct 1;184(4):1561-6; Hsu SM, et
al, Expression of interleukin-6 in Castleman's disease, Hum Pathol., 1993 Aug;24(8):833-9; Yoshizaki
K, et al, Pathogenic significance of interleukin-6 (IL 6/BSF-2) in Castleman's disease, Blood, 1989
Sep;74(4):1360-7; Nilsson MB, et al, Interleukin-6, secreted by human ovarian carcinoma cells, is a
potent proangiogenic cytokine, Cancer Res., 2005 Dec 1;65(23):10794-800; Toutirais O, et al,
Constitutive expression of TGF-betal, interleukin-6 and interleukin-8 by tumor cells as a major
component of immune escape in human ovarian carcinoma, Eur Cytokine Netw., 2003 Oct-Dec;14(4):246-55;
Obata NH, et al, Effects of interleukin 6 on in vitro cell attachment, migration and invasion of human
ovarian carcinoma, Anticancer Res., 1997 Jan-Feb;17 (lA):337-42; Dedoussis GV, et al, Endogenous
interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human
leukemic cell line, Exp Cell Res., 1999 Jun 15;249(2):269-78; Borsellino N, et al, Blocking signaling
through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and
sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity, Cancer, 1999 Jan
1;85(1):134-44; Borsellino N, et al, Endogenous interleukin 6 is a resistance factor for cis-
diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines,
Cancer Res., 1995 Oct 15;55(20):4633-9; Mizutani Y, et al, Sensitization of human renal cell carcinoma
cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-
interleukin 6 receptor monoclonal antibody; Cancer Res., 1995 Feb 1;55(3):590-6; Yusuf RZ, et al,
Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation, Curr Cancer Drug Targets,
2003 Feb;3(1):1-19; Duan Z, et al, Overexpression of IL-6 but not IL-8 increases paclitaxel resistance
of U-20S human osteosarcoma cells, Cytokine, 2002 Mar 7;17(5):234-42; Conze D, et al, Autocrine
production of interleukin 6 causes multidrug resistance in breast cancer cells, Cancer Res., 2001 Dec
15;61(24):8851-8; Rossi JF, et al, Optimizing the use of anti-interleukin-6 monoclonal antibody with
dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including
biological aspects, Bone Marrow Transplant, 2005 Nov;36(9):771-9; 그리고 Tonini G, et al, Oxaliplatin
may induce cytokine-release syndrome in colorectal cancer patients, J BiolRegul Homeost Agents, 2002
Apr-Jun;16 (2):105-9; 이들 각각의 내용은 본 발명에 그 전체가 참조로서 편입된다).
공개특허 10-2011-0091780
본 발명의 또 다른 구체예에서, 본 명세서에서 기술된 항-IL-6 항체, 또는 이들의 단편은 허혈성 심장 질환, 동
- 127 -